Skip to main content
Log in

Empfehlungen noch unheitlich

Pneumokokken-Schutz: Stellenwert der neuen Konjugatimpfstoffe

Pneumococcal vaccination: the new conjugate vaccine

  • FB_Schwerpunkt-Übersicht
  • Published:
MMW - Fortschritte der Medizin Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Jessica Rademacher.

Ethics declarations

J. Rademacher: Forschungsunterstützung: BMBF (German Ministry of Research and Education), Innovationsfond; Vortragstätigkeit: AstraZeneca, Boehringer, GSK, Chiesi, Novartis, ThermoFisher, Berlin-Chemie, Boeringer, Shionogi, MSD; Advisory Board: Shionogi, GSK, GILEAD, ThermoFisher.

C. Bahrs war Mitglied des wissenschaftlichen Beirats von GSK und hat in der Vergangenheit Reisekostenunterstützung für wissenschaftliche Konferenzen von Gilead und Pfizer erhalten.

Supplementary Information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rademacher, J., Bahrs, C. Pneumokokken-Schutz: Stellenwert der neuen Konjugatimpfstoffe. MMW - Fortschritte der Medizin 165, 40–42 (2023). https://doi.org/10.1007/s15006-023-2545-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15006-023-2545-4

Keywords:

Navigation